These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7075106)

  • 1. Cardiac hyper- and hyporesponsiveness after pindolol withdrawal.
    Rangno RE; Langlois S; Stewart J
    Clin Pharmacol Ther; 1982 May; 31(5):564-71. PubMed ID: 7075106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol.
    Rangno RE; Langlois S
    Am Heart J; 1982 Aug; 104(2 Pt 2):473-8. PubMed ID: 7102534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrupt withdrawal of pindolol or metoprolol after chronic therapy.
    Szécsi E; Kohlschütter S; Schiess W; Lang E
    Br J Clin Pharmacol; 1982; 13(Suppl 2):353S-357S. PubMed ID: 7104154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.
    Rangno RE; Langlois S
    Br J Clin Pharmacol; 1982; 13(Suppl 2):345S-351S. PubMed ID: 6125187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metoprolol withdrawal phenomena: mechanism and prevention.
    Rangno RE; Langlois S; Lutterodt A
    Clin Pharmacol Ther; 1982 Jan; 31(1):8-15. PubMed ID: 7053309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intrinsic sympathomimetic activity on beta-receptor responsiveness after beta-adrenoceptor blockade withdrawal.
    Walden RJ; Bhattacharjee P; Tomlinson B; Cashin J; Graham BR; Prichard BN
    Br J Clin Pharmacol; 1982; 13(Suppl 2):359S-364S. PubMed ID: 6125188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule.
    Rangno RE; Nattel S; Lutterodt A
    Am J Cardiol; 1982 Mar; 49(4):828-33. PubMed ID: 6278914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rebound phenomena following gradual withdrawal of chronic metoprolol treatment in patients with ischemic heart disease.
    Olsson G; Hjemdahl P; Rehnqvist N
    Am Heart J; 1984 Sep; 108(3 Pt 1):454-62. PubMed ID: 6475710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.
    Walden RJ; Tomlinson B; Graham B; Liu JB; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):557-65. PubMed ID: 1981318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of beta-blocking drugs.
    Walden RJ; Hernandez J; Yu Y; Al-Khader A; Prichard BN
    Am Heart J; 1982 Aug; 104(2 Pt 2):515-20. PubMed ID: 6125098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial sensitivity to isoproterenol following abrupt propranolol withdrawal in conscious dogs.
    Webb JG; Newman WH; Walle T; Daniell HB
    J Cardiovasc Pharmacol; 1981; 3(3):622-35. PubMed ID: 6168842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of propranolol withdrawal phenomena.
    Nattel S; Rangno RE; Van Loon G
    Circulation; 1979 Jun; 59(6):1158-64. PubMed ID: 436208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences.
    Krukemyer JJ; Boudoulas H; Binkley PF; Lima JJ
    Am Heart J; 1990 Sep; 120(3):572-9. PubMed ID: 2389694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol.
    Vandongen R; Margetts B; Deklerk N; Beilin LJ; Rogers P
    Br J Clin Pharmacol; 1986 Jun; 21(6):627-32. PubMed ID: 3741714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration.
    Aarons RD; Nies AS; Gal J; Hegstrand LR; Molinoff PB
    J Clin Invest; 1980 May; 65(5):949-57. PubMed ID: 6102572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.
    Tomlinson B; Cruickshank JM; Hayes Y; Renondin JC; Lui JB; Graham BR; Jones A; Lewis AD; Prichard BN
    Br J Clin Pharmacol; 1990 Nov; 30(5):665-72. PubMed ID: 1980200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
    Roberts DH; Tsao Y; Grimmer SF; Winstanley PA; Orme ML; Breckenridge AM
    Br J Clin Pharmacol; 1987 Aug; 24(2):163-72. PubMed ID: 2887190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.
    Aellig WH
    Br J Clin Pharmacol; 1982; 13(Suppl 2):187S-192S. PubMed ID: 6125169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hemodynamic and neurohumoral effects of pindolol: a beta-adrenoceptor antagonist with high intrinsic sympathomimetic activity in patients with dilated cardiomyopathy.
    Majid PA; Niznick J; Nishizaki S; Morris WM; Sole MJ
    J Cardiovasc Pharmacol; 1987 Sep; 10(3):309-14. PubMed ID: 2444779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.